Status:
TERMINATED
3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The objective of this study is to evaluate the feasibility of 3T magnetic resonance spectroscopic imaging (MRSI) of the prostate in improving the spectral resolution, using a perfluorocarbon compound ...
Detailed Description
MRSI is a type of magnetic resonance imaging (MRI) that uses the same type of scanner as a standard MRI. Unlike standard MRI, which takes pictures of the anatomy (body regions), MRSI takes pictures of...
Eligibility Criteria
Inclusion
- Newly diagnosed biopsy proven prostate carcinoma who are referred to Diagnostic Imaging for magnetic resonance imaging (MRI) / magnetic resonance spectroscopic imaging (MRSI)
- No previous radiation to prostate or pelvis
- No hormonal treatment for prostate
- The interval between the biopsy and magnetic resonance spectroscopic imaging (MRSI): more than 6 weeks
- Informed consent
Exclusion
- Contraindications for MRI (e.g. cardiac pacemaker)
- Allergy to Latex
- Contraindications for magnetic resonance spectroscopic imaging (MRSI) (e.g. history of abdomino-perineal resection of rectum)
- Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic field
- Previous prostate surgery for prostate carcinoma (including, transurethral resection of the prostate (TURP) and cryosurgery), local or systemic treatment for prostate carcinoma (e.g. radiation, androgen deprivation), pelvic radiation (e.g. rectal cancer), rectal surgery, BCG for bladder cancer
- Children (\<18 years)
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00429338
Start Date
January 1 2007
End Date
October 1 2013
Last Update
January 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030